Hope For Pdcd Foundation
501C3 Nonprofit Organization Information
Hope For Pdcd Foundation is a 501(c)(3) charitable nonprofit in Folsom, California (EIN 92-0361943). It has been tax-exempt since October 2022, and contributions to it are tax-deductible. Its Form 990 for tax year 2025 reports total revenue of $325,204 and net assets of $640,308. TaxExemptWorld has Form 990s on file for 4 tax years (2022–2025). The IRS classifies its activity as Birth Defects, Genetic Diseases Research (NTEE H20). It is one of 675 nonprofits in Folsom, CA.
Form 990 · Tax period ending Dec 2025 · Filed May 14, 2026 · From the IRS e-file data
Dollar amounts for every revenue and expense line are in the full 990 report.
Mission (as filed): Support and fund the development of life-saving treatment for patients with pyruvate dehydrogenase complex deficiency and related genetic diseases The activities of the foundation include providing grant funding to hospitals and medical research facilities which are conducting medical research for understanding and treatment of this condition The foundation also provides funding to individuals that assist with early patient identification through newborn screening for this condition.
The foundation makes annual grants to tax exempt medical research facilities which conduct research in a variety of fields related to PDCD which will further the foundations mission of expanding the understanding and treatment of this condition This was a payment for University of Texas Southwestern UTSW Medical Facility as part of OTD Contract SRA202503-0012 AMND 1. to conduct gene therapy research for PDHA1 genetic mutations causing Pyruvate Dehydrogenase Complex Deficiency including but not limited to synthesis of vector design and development of a mouse colony and AAV vector manufacture.
Childrens Hospital of Philadelphia Activity Assay focuses on optimizing the detection of acetyl-CoA which is crucial for PDCD within the mass spectrometry instruments sensitivity range. The study compares media versus cells with reduced interference. Various PDCD lines mild vs. severe will be examined and contrasted. Additionally PDCD will be compared with other tricarboxylic cycle deficiencies and ETC defects to ensure distinguishability.
PDHA1 ASO Designs. Jim McSwiggen of McSwiggen Biotech Consulting is evaluating whether potential genomic targets in PDHA1 exist that may be targetable.
PDCD advocacy communications services
Public charity (509(a)(1), 170(b)(1)(A)(vi))
Prepared by TaxExemptWorld from IRS Form 990 e-file data (object ID 202621349349305817). Not an official IRS form.